About NetScientific Plc

NetScientific Plc is a holding company, that invests in, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies, which offer significant growth potential in predominately the UK and USA, as well as globally.

The Group leverages trans-Atlantic relationships and global opportunities to deliver shareholder value. NetScientific looks to maximise shareholder returns through focused execution of its investment strategy with current portfolio companies, and targeted investments in existing and new investments.

NetScientific develops a customized investment and realisation strategy for its portfolio companies by adding value through management, incubation, advisory services and fund-raising support.

The group facilitates the companies it works with, to access the right type of funding, proactive management support and resources specific to their sector, stage of development and available opportunities.

Business model

NetScientific’s business model is based on identifying, investing in, and helping to build game-changing companies in the life sciences and sustainability areas. We target tangible value inflection points and eventual release of value through partial or full exits through trade sales or public listing. We work pro-actively with the companies to get through these value inflection points, to the point where we can release value through various exit options. We use a leveraged investment model, whereby NetScientific’s balance sheet investments are leveraged through syndication and partnering with other investors.

NetScientific’s business strategy is based on funding and building game-changing healthcare and technology companies towards value inflection points and eventual exit including through a trade sale or public listing.

Portfolio value growth strategies

 The Group aims to grow the value of its interests in its portfolio companies through various key value inflection points relevant to their business models and industry of focus. These may include early corporate validation of a technology, industry partnerships, clinical trials, regulatory approvals, collaborative funding arrangements, first revenues and follow-on growth. In turn, these value inflection points create early liquidity opportunities, including partial disposals, trade sales, out-licensing opportunities and IPOs. We leverage our network of corporate relationships both to validate the opportunities and to accelerate the growth of the Portfolio Companies.

Deal sourcing

 The Group sources opportunities from its global network of investors, research institutions, corporate relationships and advisors.
Pro-active management: The Group has a pro-active management approach, often taking a Board seat and supporting portfolio companies with technical guidance, access to expertise and specialised investment, IP strategy, corporate licensing and business growth capabilities through our expanded team and networks..
As companies mature through key milestones the Group works to help the companies identify the right leadership and corporate partners for scale-up, attract additional external capital and secure favourable exits.

Leveraged investment approach

We pursue a leveraged investment approach, whereby the Group’s backing and investment can leverage external investment from a mixture of private, corporate and institutional investment sources. In addition, we encourage and support portfolio companies’ access to non-dilutive funding such as public sector grants and corporate JDAs.

EMV Capital

 Our subsidiary company, EMV Capital (www.emvcapital.com) is an investor and corporate finance specialist. EMV Capital’s model is to syndicate investments between financial and corporate investors, and to take a hands-on role post-investment with a focus on venture capital-type returns. It works alongside our portfolio companies to develop a customized investment strategy for each portfolio company and provide access to a blend of private, corporate and institutional finance sources. EMV Capital combines an EIS investment practice, family office, Corporate VCs and institutional VCs. The diverse sources enable the development of investment strategies that are appropriate for technology companies as they go through the technology and business growth life cycles.

Corporate co-investment model

EMV Capital and NetScientific have originated and executed co-investments with Corporate venture capital involvement, and have helped develop corporate collaborations. This capability and the growing network of corporate contacts provides deal flow, validation partners, routes to market and routes to exit for portfolio companies.

Exits and Realisation

We look for the most appropriate points to realise value. The most appropriate and realistic exit opportunities can vary over time, within and between industries. In addition to IPOs, realisations can be through trade sales to strategic buyers, spin-outs, licensing arrangements, secondary sales to other financial investors, amongst others.

Our growth and investment strategies take into account sectoral specificities. Below is an outline of some of the strategies we pursue

Healthcare investment strategy

Building businesses that fight chronic diseases on three fronts

Using data to provide clinical-grade actionable insight. We are focused on identifying, investing in and growing teams developing solutions that can make a real difference to the problems faced by today’s and tomorrow’s healthcare systems. Our dual access to the US and European healthcare markets positions us uniquely well to help companies on either side of the Atlantic maximize their growth opportunities.

Digital Health & Diagnostics

Using data and AI to provide actionable insights as relevant to clinical and non-clinical settings for healthcare systems in the US, Europe and internationally.
Novel highly specific tests to provide earlier diagnosis, accurate monitoring of disease progression and the ability to personalize therapy based on an understanding of an individuals ability to respond to treatment.
Helping accelerate the route to market by supporting companies to commercialise their offering, such as through identifying reimbursement and Lab Developed Test strategies in the US market, or supporting points of entry in the UK and European healthcare systems.


Targeting novel mechanisms of actions, new targeted delivery methods and safe but highly personalized therapeutic options to significantly improve or cure the disease. Helping the companies identify the right corporate and public sector partnerships, CRO relationships, and optimizing the capital expenditure and funding structure.

Tackling the biggest challenge in life sciences/healthcare

89.1 million people with the major 4 chronic conditions live in the US. A growing figure due to ageing populations

$1.7 trillion spend p.a. fighting chronic conditions in US

€700 bn/year spend p.a. in Europe on chronic diseases

86% of deaths in Europe are due to chronic diseases

14m new cases p.a. and 8.2m deaths p.a. due to Cancer, one of the world’s biggest killers

31% of all deaths globally due to cardiovascular diseases account for 31% of all deaths worldwide

(Source: WHO, European Commission)


Sustainability investment strategy

Our team has expertise and experience in the various sectors making up the sustainability investment space


The Energy transition is underway, with a clear need for cleaner and more sustainable ways to generate, store, and use energy. Innovations to the energy efficiency of existing equipment and assets are as critical as investing in a clean supply of energy, with technology across a broad range of disciplines providing important contributions to the global energy balance.

Smart Cities and Connected Transport

There is great societal value in making cities smarter and transport safer through advances and innovations in connectivity, communications, and data optimization. Autonomous and electric vehicles are the future of transport, with technology barriers being broken down through pioneering engineering throughout the vehicle systems and through integration with the world around them.

Circular Economy

We see huge potential for innovation as a driving force behind the transition to a circular economy. Across all sectors, a focus on resource efficiency and implementing circular economy business models will not only lead to a large sustainability impact but will also increase the efficiency of production and provide supply-chain benefits through intelligent waste management.

Industrial High-Tech

We see huge potential for innovation as a driving force behind the transition to a circular economy. Across all sectors, a focus on resource efficiency and implementing circular economy business models will not only lead to a large sustainability impact, but will also increase the efficiency of production and provide supply-chain benefits through intelligent waste management.

About Us